7,182 press releases indexed under healthcare.
Follow-Up to August 31 Announcement: First Cohort Process Is Now Open for Real-World Image Testing
Expands Nanox’s growing U.S. distribution network with a leading New England-based medical imaging provider
Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt’s disease, a potentially blinding disease with no FDA-approved therapy
As Canada's New Brunswick province commits $4 million to expand its Nursing Home Without Walls program — and nursing home waitlists swell to nearly 1,000 patients — the conversation around aging in place has shifted from preference to urgent necessity. SonderCare, a premium home hospital bed manufacturer with over 25 years of healthcare expertise, says the policy momentum is meaningful, but its impact depends entirely [PR.com]
Consumer Product Events Reveals Its Favorite Beauty + Wellness Brands Worth Buying Now, Spotlighting the Products Winning Over Today's Selective, Health-Conscious Shopper MALIBU, Calif., Sept. 4, 2026 /PRNewswire/ -- As U.S. beauty sales climb 7% and the industry's $56 billion "feel-good...
(PR-inside.com) Jaguar remains sharply focused on its ongoing global development program for oral crofelemer as adjunctive therapy to parenteral support (PS) for pediatric and adult rare IF diseases, including microvillus inclusion disease (MVID) Company plans to file NDA for crofelemer for MVID in mid-2027 to obtain FDA approval SAN FRANCISCO, CA / ACCESS Newswire / September 4, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Jaguar family company Napo Pharmaceuticals (Napo) is providing the company's novel crofelemer powder for oral solution for treatment of intestinal failure (IF) in an infant patient due to congenital sodium diarrhea (CSD), which is caused by ..
Jaguar remains sharply focused on its ongoing global development program for oral crofelemer as adjunctive therapy to parenteral support (PS) for pediatric and adult rare IF diseases, including microvillus inclusion disease (MVID) Company plans to file NDA for crofelemer for MVID in mid-2027 to obtain FDA approval
In this free webinar, learn how hybrid monitoring can strengthen oversight and study execution in in vitro diagnostic (IVD) clinical studies. The featured speakers will discuss how sponsor delegation, centralized oversight and on-site monitoring can support regulatory compliance, quality...
The post Quest Slimming & Beauty Recognized by ThreeBestRated® 2026: Tanya Reflects on the Clinic's Journey first appeared on
(PR-inside.com) NEW YORK, NY / ACCESS Newswire / September 4, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Fractyl Health, Inc. (NASDAQ:GUTS) securities. If you suffered a loss on your Fractyl Health, Inc. investment and would like to explore a potential recovery under the federal securities laws, Learn about Fractyl Health, Inc. Class Action or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit was filed against ..
(PR-inside.com) SAN DIEGO, CA / ACCESS Newswire / September 4, 2026 / Modular Medical, Inc. ("Modular Medical" or "the Company") (NASDAQ:MODD), a commercial-stage medical device company preparing for the commercial launch of its next-generation Pivot™ tubeless patch pump, today announced that it has secured a contract with a national U.S. pharmacy benefit manager (PBM) in the United States. Pursuant to the contract, the Company's Pivot insulin delivery system is now available through the national PBM. The Company believes the engagement with this national PBM represents a significant step forward in broadening patient access to the Company's Pivot tubeless patch pump and ..